Tizanidine as an Adjunct to Alpha‐Blockers in Adults With Dysfunctional Voiding/Poor Relaxation of the External Sphincter: A Retrospective Review
LUTS: Lower Urinary Tract Symptoms · 2026-07 · 18 (4)
DOI: 10.1111/luts.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 22.06.2026. Verfasst von Mayank Mohan Agarwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Apollomedics Superspeciality Hospitals, Lucknow, India. Hauptthemen laut MEDLINE: Clonidine, Adrenergic alpha-Antagonists, Urination Disorders, Adrenergic alpha-2 Receptor Agonists. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
Skeletal muscle relaxants (SMR), particularly baclofen, have been used in patients with dysfunctional voiding (DV) and poor relaxation of the external sphincter (PRES) with variable efficacy and notable side effects. Tizanidine, a centrally acting α 2‐adrenergic agonist, may offer comparable benefits with a more favorable tolerability profile. However, data regarding its use in DV remain limited.
Methods
This retrospective analysis included adults diagnosed with DV/PRES between July 2017 and January 2025. Data comprised demographics, lower urinary tract symptoms (LUTS), urodynamic parameters, pre, and posttreatment uroflowmetry values, and subjective response to alpha‐blockers with pelvic floor relaxation exercises, and subsequent addition of tizanidine. Uroflowmetry indices included Qmax, Qave, and volume‐normalized flow indices (VQImax, VQIave). Clinical outcomes were assessed via patient‐reported symptom improvement.
Results
Of 114 patients, 62.2% showed no response to alpha‐blockers alone. Following addition of tizanidine (median dose 6 mg/day), 69.3% reported symptomatic improvement (45% ≥ 50% improvement, 24.6% < 50% improvement; p < 0.00001). VQImax improved by ≥ 50% in 52% of patients, and clinical improvement significantly correlated with changes in VQImax ( p = 0.004) and VQIave ( p = 0.009). Women demonstrated greater improvement in flow parameters than men ( p < 0.05), although symptom relief was similar across sexes. Tizanidine was generally well tolerated, with sedation being the most common dose‐limiting side effect (25%). Median follow up duration was 12 months (IQR 9–22).
Conclusions
Addition of tizanidine to alpha‐blocker and pelvic relaxation is associated with clinically significant improvement in LUTS and uroflometry parameters in adults with pelvic floor dysfunction. We acknowledge that causal inference is limited by the study design and randomized placebo‐controlled studies are required for deriving stronger conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Apollomedics Superspeciality Hospitals, Lucknow, India.
ORCID-Profile: Mayank Mohan Agarwal, Shailendra Kumar Gupta
Zitieren
APA
Agarwal, M. M., Bhaskar, V., Gupta, S. K., Singh, S., Chowdhary, S. K., Mishra, V., Agnihotri, R., & Rathore, D. K. (2026). Tizanidine as an Adjunct to Alpha‐Blockers in Adults With Dysfunctional Voiding/Poor Relaxation of the External Sphincter: A Retrospective Review. LUTS: Lower Urinary Tract Symptoms, 18(4). https://doi.org/10.1111/luts.70077
Vancouver
Agarwal MM, Bhaskar V, Gupta SK, Singh S, Chowdhary SK, Mishra V, et al. Tizanidine as an Adjunct to Alpha‐Blockers in Adults With Dysfunctional Voiding/Poor Relaxation of the External Sphincter: A Retrospective Review. LUTS: Lower Urinary Tract Symptoms. 2026;18(4). doi:10.1111/luts.70077
BibTeX
@article{Agarwal2026,
author = {Agarwal, Mayank Mohan and Bhaskar, Ved and Gupta, Shailendra Kumar and Singh, Saumya and Chowdhary, Shakti Kumar and Mishra, Vikrant and Agnihotri, Rahul and Rathore, Devendra Kumar},
title = {Tizanidine as an Adjunct to Alpha‐Blockers in Adults With Dysfunctional Voiding/Poor Relaxation of the External Sphincter: A Retrospective Review},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2026},
volume = {18},
number = {4},
doi = {10.1111/luts.70077}
}
EUVIMED